首页|非酒精性脂肪肝病中的免疫作用及干细胞疗法的前景

非酒精性脂肪肝病中的免疫作用及干细胞疗法的前景

扫码查看
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)作为普遍的慢性肝脏疾病,由肝细胞内三酰甘油聚集引发免疫系统参与,并伴随组织学改变.NAFLD是一种进展性疾病,炎症反应被认为是NAFLD进展的驱动力,涉及代谢损伤的各种触发因素通常会导致不同免疫细胞的激活.针对NAFLD的特异性药物治疗仍然缺乏.来自干细胞的外泌体是一种低免疫原性的新型疗法,被用来抑制组织中的免疫反应.该文旨在探究NAFLD的发病机制以及肝脏对人体免疫的重要性,重点讨论不同免疫细胞在NAFLD发病及进展中的作用,深层次理解免疫细胞参与NAFLD的发病机制,对目前免疫疗法进行总结,为设计新的免疫疗法提供理论支撑.
The mechanism of immune system action in non-alcoholic fatty liver disease and the prospects for stem cell therapy
Nonalcoholic fatty liver disease(NAFLD),as a widespread chronic hepatic disease,is caused by the accumulation of hepatocellular triglyceride,instigating immunological engagement and accompanied by histopathological alterations.NAFLD's a progressive ailment,and the inflammatory response is the driving force in the progression of NAFLD,with various triggers involving metabolic damage often leading to the activation of different immunocytes.The specific drug for NAFLD remains deficient.Stem cell-derived exosomes,representing an innovative therapeutic modality with minimized immunogenicity,are used to suppress the immune reactions in tissues.This article aimed to explore the pathogenesis of NAFLD and the importance of liver in human immunity,discuss the role of different immunocytes in the pathogenesis and progression of NAFLD,deeply understand the pathogenesis of immunocytes involved in NAFLD,summarize the current immunotherapy,and to provide theoretical support for the design of new immunotherapy.

immune responsenon-alcoholic fatty liver diseasestem cell exosomesimmunotherapy

白鑫、刘珉宇

展开 >

中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437

上海市生物物质成药性评价技术服务平台,上海 200437

免疫反应 非酒精性脂肪肝病 干细胞外泌体 免疫疗法

2024

世界临床药物
上海医药工业研究院

世界临床药物

CSTPCD
影响因子:0.849
ISSN:1672-9188
年,卷(期):2024.45(5)
  • 35